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This examination consists of tro ecstiona'
geatLol I consists of 50 nultiple choice questions
SrctLon E consists of tro (2) long questions
Answer ALL questions
Answer to section A must be entered into the scripts
provided.
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related to ltE abiLity to reduce cereb,rosp.inalfluid (csf) Production.
related to its abitity to reduce the leakiness of
bl,ood brain barrier.
related to its ability to shift oxygendissociation curve.
all of the above.
1. glhich of the following statement regarding the use of
mannitol in increased intracranial pressure (ICP) is true?
(a) It should be given parenterally.
(b) The use should not be longer than 3 days.
(c) It nay induce osmotic diuresis.
(d) All of the above are true.
The use of high dose pentobarbitone in the manaqtement of ICPis/are r....
The use
indicated in vasogenic IcP.
indicated in obstructive ICP.
the first line manage.ment of ICP related togeneralised edema.
all of the above.
corticosteroids in the management of ICP is/are..
2.
3.
{a}
(b)
(c)
(d)
of
(c)
(d)
(a)
(b)
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4. Mechanism of action of diuretics in reducing ICP is .... " '
..... (a) by reducing total body wat,er.
..... (b) by decreasing CSF production.
.., o. (c) bY inProving CSF flow.
(d) by decreasing the rate of the brain metabolism.
5. The use of hyperosmolar agents in the management of IcPis/are..
.....(a)associatedwiththereductionoftotalbody
water.
(b) associated with an increase in the serum
osmolarity.
..o..(c}veryusefulinthelCPassociatedwiththepresence of mase lession.
..... (d) all of the above'
6. Normal intracranial pressure is .....
. o .. . (a) 15 torr.
.. ... (b) 15 mm Hg.
(c) 15 mm HZO.
(d) none of the above.
7. Prolonged use of mannitol is/are not encouraged due to' o " "
(a) severe rebound Phenomenon.
(b) reduction in j-ts effectiveness.
(c) severe hYPerosmolar coma.
(d) all of th6 above
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8. !{hlch of the fo}lowing statenents regarding hlpothermia inICP is true?
(a) It is useful in controlling rCn in children
not responding to mannitol.
(b) ft reduces the ICP by regulating the rate of
respiratd-dn.
..... (c) Reduction of body tenperature down below 32oC is
al.ways associated with arrhythmias.
o.... (d) All of the above are true.
9. llhich of the following stateurents is true regarding
combination therapy in ICP?
..... (a) Coubination of mannitol and frusenide is thefirst line pharmacologic therapy.
(b) Courbination of hypothernia and barbiturate is
associated with tachycardia.
..... (C) Combination of cortisosteroid and barbiturateis reconnended in wsogenlo ICP
(D) AIl of the above.
10. Which of the following is/are the best non-drug therapy in
ICP secondary to head injury?
..... (a) Hyperventilation,
(b) Elevation of head by.3oo.
(c) Reduction in fluid supplernent.
o.... (d) All of the above are true.
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11.$hichofthefol].owingdrugsisthemosteffectiveinthe
management of nlgraine ?
. e,.. (a) Ergotamine'
e . o.. (b) ProPranol-oL'
(c) Mefenamic acid.
o.... (d) CarbanazePine'
t2. which of the following statement regarding migraine is
true?
.. o.. (a) lt[3"*. usually occurs 24 hours 
prior to an
..... (b) Pulsatile pain is due to vasodilation'
...-. (c) The use.of cinnarizine-is very effective inpi""""ting classical migraine'
..... (d) All of the above are true'
13.Whichofthefollowinganalgesicisthebestchoicefor.
migraine attack ?
..... (a) AsPi-rin'
(b) Paracetamol'
(c) Piroxicam.
.,... (d) Diclofenac Sodiuut'
319
...6/-
-6 (FCP 555)
INDEX NO:
L4. I{hich of the following non-drug therapy ls/are effective in
reducing the duration of migraine attack?
..... (a) Regular exercise.
(b) AvoLdance of mental tenEion.
. . . o o (c) Stay in the darlc room and sleep.
..... (d) All of the above.
15. Which of the foll.owing statenents regarding nigraine is
true?
,,.. o (a) prophylaxis therapy is indicated in patient with2 or more attacks Per Year.
(b) Beta-blockers iE the most effective drug for
the prophylaxis of classical migraine.
(c) cinnarizine act by preventing vasodilation prlorto an attack.
(d) AlI of the above are true.
16. Which of the following sequence regarding the choice
of ICP therapY is true ?
o.... (a) Mannitol > corticosteroid > phenobarbitone.
(b) Mannitol > phenobarbitone > corticosteroid.
(c) corticosteroid > nannitol > phenobarbitone.
(d) Phenobarbitone > mannitol > corticosteroid.
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L7. which of the following statement regarding thepathophysiology of migraine is true?
(a) Migraine is a nanifestation of sequence of
vasoconstriction and vasodilatlon of the extra
and intracranial arteries'
(b) Platelet aggregation is the nain cause of
claEsical migraine'
..... (c) Migraine that occurs after an episode of stress' is-due to increased ICP
..... (d) AII of the above are true'
18. Postural hypotension is corumonly^k1-ow1 to--occur in apsychiatric patient treaiea with tfrJ foffowing antipsychotic
drugs excePt...
..... (a) ChlorPromazine'
(b) Thiori.dazine.
(c) ClozaPine'
.... t (d) Thiothixene'
19. t{hich of the following mechan}:I.of action of the anti-Ft;il"ii.-d""g"-is trrle tor rithiurn carbonate ?
'.... 
(a) It blocksthe D1 and D2 receptors'
,..., (b) It inhibitsthe reuptake processes'
..... (c) It intefereswith the storage of neurotransnitter' and sodium-Potassium PumP'
...'.(d)ItniniGtheneurotransmitteratthestorageand
receptor site.
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20. The following statenents concerning the principles of
neuroleptic use are true except r. o..
(a) neuroleptics are target synptom specific rather
than diEease specific.
(b) they are not effectlve in rrnon-productiverl
slmptoms.
(c) there is a significant difference between the
neurolept,ics in their effectiveness.
(d) the dose of neuroleptic Ehould be reduced to theleast possible dose once psychosis is
controLled.
2L. The abnorrnality in Parkinsonrs disease is due to the .......
22. l{hich
(a) degeneration of the lateral nucleus of the
thalamus.
(b) degeneration of the subthalamic nucleus.
(c) loss of pallida1 neurons.
(d) loss of substantia nigra neurons.
of the following is not a cause of Parkinsonism ?
(a) Reserpine treatment'
(b) A focal lesion of the brain.
(c) Encephalitis Lethargica.
(d) Carbon nonoxide Poisoning.
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23. t{hich of ttre folLowing i8 a therapy for idiopathic
Parkinsonism ?
.... r (a) ProchlorPerazine.
(b) Amantadine.
..... (c) Thalanotomy.
(d) Prednisolone.
24. The most effective drug in the treatment of Parkin5onrs
diseasg is .,.......
..... (a) levodoPa.
.... o (b) anticholinergic.
(c) bromocriPtine.
(d) monoaitiae oxidase inhibitors (!{AOI) '
25. The rnost common etiology for Parkinsonism is " " " "
(a) tumors.
(b) trauma.
(c) infection.
(d) idiopathic.
26. The type of trenor observed in Parkinsonism is o...... o
. c... (a) intentional trenor.
..... (b) Postural tremor-
(c) resting tremor.
(d) action tremor.
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21. Which of the following drug would
and cauEe hypertensive crisis ?'
(rcP 555)
interact with levodopa
..... (a) PhenYtoin.
o...o (b) Pyridoxine.
... !. (c) uethyldoPa.
o.... (d) I.{AOI.
28. !{hich of
disorder
the
?
following is regarded as typical extrapynanidal
(a) ft disappeat€during sleeP.
(b) It is relieved bY alcohol.
(c) It is not affected bY stress.
(d) It is characterised by weakness.
29. Which of the fotrlowing neuroleptic has the highestpotential to induce extrapyranidal syndrome (EPS) ?
. . . . . (a) Fluphenazine.
. . . . . (b) ChlorPromazine.
.. c.. (c) Perphenazine.
. . . . . (d) llesoridazine.
30. Acute dystonia slmptoms usually affect the
..... (a) head and neck area of the body.
..... (b) upper llnbs.
..... (c) lower limbs.
..... (d) niddle portion of the body.
raaaa.a.a
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31. Anticholinergics is not enployed in the treatment of....... -
..... (a) acute dystonia.
..... (b) akathisia.
. . . . . (c) pseudoparkinsonism.
..... (d) tardive dyskinesia.
32. I{hich of tlre following EPs is characterised by internal
motor restlessness ?
. o. . . (a) AkathiEia,
..... (b) Dystonia.
(c) Pseudoparkinsonisn.
(d) Tardive dyskinesia.
33. The antibody involved in the destruction of the post-junctional end-plate acetylcholine receptors in
myaesthenia gravis is the . r r..... tyPe.
..... (a) IgG.
(b) IsM.
.. .. . (c) IgE.
(d) all of the above.
34. Which of the following anticholineeteraEe is being employedin the comfirmatory test of myaesthenia gravis ?
.... r (a) Edrophoniun chloride.
(b) Ambenoniurn chloride.
(c) Pyridostigrmine bromide.
(d) Neostigrnine bronide.
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35. I{hich of the followlng anticholinesterase has the longestduration of action ?
,..,. (a) Edrophoniun chloride'
..... (b) Anbenoniun chloride.
.. o.. (c) Pyridostignmine bronide.
..... (d) Neostigrmine bronide.
36. The main cause of death in myaesthenia gravis patients i8.....
. . . . . (a) cardiovascular problens.
..... (b) liver dYsfunction.
..... (c) renal failure. '
(d) respiratorY weakness.
37. The reason that hoepitall,zatlon is recomrnended when a
myaesthenia grariis patient is to be started on
corticosteroid is. . .. . . . .
..... (a) the inittation r dose is very high.
..... (b) it is usual for patients above 50 years of
age.
. ... . (c) it, augrments muscle weakness initially.
. .. .. (d) it usually cause's severe hypertension.
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optimal dose of anticholinesterase would
restore the muscle strength to . " .. " '
strength.
13
(a) visual..
(b) somatic.
(c) persecutory.
(d) tactile.
(a) thioridazLne.
(b) trifluoPerazine.
(c) chlorPromazine
(d) perphenazine.
(rcP 555)
only be able
of the normal
the most anticholi-
38.
..... (a) 20 Percent.
..... (b) 40 Percent.
..... (c) 6o Percent.
.. . .. (d) 80 Percent,
39. The following is a type of hallucination except " ! " "
40. characteristic features of schizophrenia is o,...
..... (a) f1iEht of idea'
. . .. . (b) elation.
(c) delusion.
(d) concrete thinking.
41. Antipsychotic drug which has
nergic side-effect is . -.....
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42. The average daily dose of chloropromazine for treatment of
acute psychotic illness is ........
o.. o. (a) 11000 ng - 11500 mg.
r,... (b) 5OO 1r0oo mg,
(c) 100 - 300 ng.
(d) 400 7OO mg.
43. Characteristic features of mania is
(a) pressure of speech.
(b) thought block.
o. o o. (c) loosening of association.
(d) flight of idea.
44. Which of the following investigation is mandatory before
starting lithiun therapy ?
(a) Liver function test.
(b) Serum creatinine.
r.... (C) Full blood picture.
(d) Serum electrolyte.
45. Tetracyclic anti-depressant available in Hospital USM is
(a) arnitriptyline.
(b) Imipramine.
(c) Dothiepin.
(d) Maprotiline.
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46. Second line drug used in the prophylactic treatment of
affective disorder is ......
o..,. (a) carbamazepine.
(b) alprazolam.
(c) haloperidol.
..,.. (d) Iithiun carbonate
47. Which of the following disorder is classified as neuroticillness ?
(a) Paranoid disorder.
(b) Neurotic dePression.
..... (c) Schizophreniform disorder'
,.... (d) Delirium.
48. Characteristic features of depression iE
(a) palpitation.
(b) tremors.
...,. (c) anorexia.
(d) obsessive idea.
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49. !{hich of the following drug is commonly used in the
treatment of anxietY neurosis ?
(a) Midazolan.
..... (b) Sodiun barbiturate.
(c) Clonazepam.
..... (d) Propranolol.
50. Behaviour treatment for anxiety disorder is
... o c (a) systenatic deEensitization.
(b) token economy.
(c) response prevention.
(d) aversion theraPY.
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SECEION B
Question 1.
Mr. I'IA is a 37 years old malay man, was referred to HUSM fromJertih Distric irospital for firrthei rnanagement of CVA post-
!{vA.
Clso aumnary Mr. MjA was otherwise healthy_until 3 days 
-199when hl was involved in a motor vehicle accident (l{vA)
while ne was riding his motorcycle. During thq incident, he
sustained a severe head injury with massive blood loss' On
admission to the Jertih Di;trLct hospital, he was found tobe unconcious with Glasgow Coma SCore of 5. During the-first 3 days in the hospiial he was give.1 .a pints of bloodi"a I litr-es of dextroje saline. In Ladition, he received
mannitol and phenytoin but failed to regain conciousness'
He lras refeired to HUSI.| for further investigation and
management.
In HUSM, a CT scan was done and the result showed a largeintracerebral hemorrhage surrounded by edema at the frontalIobe. However, ttrere ias no sign of persistent bleeding'Various }aboratory test-swere ordered and the resultshtere
still pending.
A. Explain the possibre mechanism for the develop:ment of in-
creased intracranial pressure in I'tA ?
B.
c.
(7 marks)
Explain the rationalefor the use of mannitol in ![e. Suggestthe monitoring plan to evaluate the effect of mannitol
therapy.
(8 narks)
Discuss other therapeutic approaches of managing increasedintracranial pressure.
(1o narks)
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Question 2.
SM, a 50 year old female cornplalned of anxiety, nervousness,
tremor and weakneas of the right hand. Her tremor and
weaknesg qrere first noticed at the tine of her husbandrs
death 5 months agc. Her conplaints were exacerbated. try stress
and worsened by pressure at work. Her secretary told herthat her handwiit.ins r is getting smaller and lrregular andher voice is changing.
Physical examination : well nourished
: well develoPed
: no acute distress
: noticeab'le ..tremor in both hands
: cogwheel rigiditY in both arms
: slightly nask like face
: siaLorrhea
Vital signs : B.P. 130/90
:T37C
: R.R 20
Laboratory tests : all within normal limits.
Diagnosis : Parkinsonrs disease
Treatment Plan : Anticholinergic.
A, What subJective and objective clinical data are compatible
with a diagnosis of Parkinsonrs disease in Slt Z
( 5 Marks )
B. Suggest an anticholinergic which is suitable for SM anddiiiuss the nonitoring parameters that should be done to
assess the efficacy and adverse effect of the drug
suggested.
( 5 Marks )
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( 10 Marks )
( 5 Marks )
c. Five months later lrer signs and slrurptons improved exceptfor her rigidity and bradykinesia which becane more
troublesotne. Livodopa wa3 then added to the.gre.scl'iption'
Discuss tne suitability of levodopa and how it shoulil beinitiated. aiso discu-ss its rnecLanism of action and
adveree drug reactions.
(D) Discuss the advantages and disadvantagel of using
carbidopa in coubinition with levodopa ?
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1. Ammonia
2. Amilase
3. Billirubin
DirectIndirect
Total
4. COa
5. pCoz
6. Cr
7. Cpk
8. Creatinine (SCr)
9. Random blood sugar
10. Iron
11. Lactic
dehydrogenase
L2. MaEnessium
13. poe
L4. pH
15. Acid phosphatase
Nornal Laboratory Values
80-110 ncg/dt or 47-65 unol/L
4-25 IU/nI
o-o.2 ng/g}0.2-0.8 ng/dl
o.2-L ng/dl
20-30 nEq/I,
35-45 nnHg
100-106 nEq/L
5O-L7A VlL
0.6-1.s ng/dl
70-110 ng/dl
50-1s0 mca/d1
7O-2LO TVIL
t.5-2.o nEg/L
75-100 nnHg
7 .35-7 .45
0-3 unol/L
30-14 unol/L
3O-t7 unol/L
24-30 nMol/L
100-106 nilol/L
60-130 umol/L
3-10 unol/I,
9.0-26.9 umol/L
o.8-1.3 ultol/L
1.0-1.5 nMol/L
3.5-s.0 nMoI/L
2.L-2.6 rnMol/L
13s-145 nMol/L
24-zg mlvtol/L
!{ale 0. 13-0 . 63 IU/nlFemale 0.101-0.65 IU/nl
16. Alkaline 39-LL7 TVII.
phosphatase
L7. Phosphorous 3.0-4.5 ng/dl
18. Potassium (K+) 3.5-5.0 nEq/L
19. calcium (ca2+) 8.5-10.5 mg/dl
2A. Sodium (Na+1 135-145 nEq/l,
2L. Bicarbonate (HCO3-) 24-38 mEg/L
36-t76 nmol 
=-1lr,2.8-156 nmol s't lL
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22. ProteinTotal 6. o-8.5 g/dl 60-85 glLAlbumin 3.5-5.0 g/dl 35-50 g/LGlobulin 2.3-3.5 g/dL 23-35 glLTransferrin 200-400 ngldl 2,o-9.o g/L
23. Transaminaee o-40 J.IJII- 0-0.32 umol 
"-Llt( scor)
24. BUN 8-25 ng/dl 2.9-8.9 mMol/L
2s. Uric Acid 3-7 ng/dl 0.18-0.42 tnMol/L
26. Blood Pictures
Red blood cell (RBC)Male 4.8-6.4 x 109/mn1
Female 4.2-5.4 x lOo/mmJ 
^White blood cell(ltBc) 4 . 0-11. O x 1or /mmJP 60-75tL 20-40*
u 4-8tB O-1*
E 1-3t
Platelate (PIt) 2oo-4OO x 103/t*t3
27. EsR Male 0-10 run/ jan (glintrobe)
Female 0-15 nn/jan (Wintrobe)
2,8. HematocritMale 45-522
Female 37-48\
29. Hemoglobine (Hgb)Male 13-18 gldLFemale L2-L6 glal
30. Prothronbin tine 75-100t nilai asas(PT)
31. APTT 25'37 saat.
32. Creatinine 105-150 n1/nin/1.73 m2
Clearance(crcl)
33. TTa 3.0-7.5 ncg/dl
34. RT3U 25-3sZ
35. FTr L.3-4.2
3E6
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NORMAL HE!,TODYNAI.ITC VALUES AND DERIVED TNDICES
sv
PVR
Normal Value Units
BP s/D/M 3ifft::ffii::;"iclMean 120 | 80 te3 mm Hs
CO Cardiac Output 4-6 Liters/nin.
RAP Right Atrial Pressure(Mean) 2-6 mn Hg
PAP S/D/!{ Pulmonary Artery Pressure 251L2/L6 mrn Hg
Systol icl Diastol ic/Mean
Pc!{P ;::::ffi:r,fi3liitarv r{edse 5-12 mm Hs
cI Cardiac Index 2.5-3.5 Liters/min/nr2
co
CI=
Body surface Area
Stroke Vo1ume 50 80 ml/beat
SV=
svr
Heat Rate
Stroke Volume Index 30 - 50 ml/beat/n2
SVI=
Body Surface Area
Pulmonary Vascular
Resistance
MPAP - PCWP
PVR= xB0
co
TPVR Total Peripheral Vascular 
-rResistance 900-1400 dynes. sec. cltl -
!{BP - RAPTPVII=- x 80
co
LVSWI Left Ventricular Stroke
work rndex 35-80 gm-rn/rn2lbeat
LvswI = (UBP-PCWP) (svr) (,0136)
337 i,
